---
title: "Beijing Tiantan Biological Products Corporation Limited (600161.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600161.SH.md"
symbol: "600161.SH"
name: "Beijing Tiantan Biological Products Corporation Limited"
industry: "Biotechnology"
datetime: "2026-05-21T07:38:04.543Z"
locales:
  - [en](https://longbridge.com/en/quote/600161.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600161.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600161.SH.md)
---

# Beijing Tiantan Biological Products Corporation Limited (600161.SH)

## Company Overview

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally. Its products include human serum albumin; intravenous human immunoglobulin; rabies immunoglobulin; tetanus immunoglobulin; hepatitis B immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex concentrate; lyophilized intravenous hepatitis B immunoglobulin; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for injection; and other blood products. The company was founded in 1966 and is headquartered in Beijing, China.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.TiantanBio.com](https://www.TiantanBio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: C (0.45)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 23 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -2.21% |  |
| Net Profit YoY | -34.14% |  |
| P/B Ratio | 2.20 |  |
| Dividend Ratio | 1.89% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 26070861653.43 |  |
| Revenue | 5980454576.31 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 8.37% | B |
| Profit Margin | 16.23% | A |
| Gross Margin | 34.59% | C |
| Revenue YoY | -2.21% | D |
| Net Profit YoY | -34.14% | D |
| Total Assets YoY | 2.71% | C |
| Net Assets YoY | 4.21% | C |
| Cash Flow Margin | 64.25% | C |
| OCF YoY | -2.21% | D |
| Turnover | 0.36 | C |
| Gearing Ratio | 7.07% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Beijing Tiantan Biological Products Corporation Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-2.21%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-34.14%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.20",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.89%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "26070861653.43",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "5980454576.31",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "8.37%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "16.23%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "34.59%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-2.21%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-34.14%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.71%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.21%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "64.25%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-2.21%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.36",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "7.07%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 26.86 | 8/81 | 27.38 | 26.13 | 25.02 |
| PB | 2.20 | 32/81 | 3.39 | 3.15 | 2.77 |
| PS (TTM) | 4.36 | 15/81 | 6.24 | 5.62 | 4.94 |
| Dividend Yield | 1.89% | 14/81 | 1.56% | 1.38% | 0.51% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-16T16:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 25% |
| Overweight | 2 | 50% |
| Hold | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 13.64 |
| Highest Target | 24.00 |
| Lowest Target | 15.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600161.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600161.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600161.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600161.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**